Local insulin: an $80 million Russia–Pakistan project, from filling to API
Zavod Medsintez and Genetics Pharmaceuticals plan an aseptic filling plant by 2028 and insulin API production by 2031.
In this article
Insulin is a medicine many patients depend on every day. A planned joint project aims to make it in Pakistan, in stages — first filling imported bulk insulin, then making the active ingredient itself.
The project
Russian pharmaceutical company Zavod Medsintez and its Pakistani partner Genetics Pharmaceuticals Private Limited plan to invest about $80 million in local insulin production, ProPakistani reported in May 2026, citing sources.
| Phase | Investment | What | Target |
|---|---|---|---|
| 1 | About $20 million | Aseptic filling plant for insulin and related products, using bulk imports | December 2028 |
| 2 | About $60 million | API production with technology transfer: insulin from API purification to final packaging | December 2031 |
DRAP has allowed the companies to market Rosinsulin R, Rosinsulin C and Rosinsulin M 30/70 in Pakistan, and will monitor the project against stage-wise investment timelines.
Why the staged model matters
Starting with filling and finishing imported bulk lets a company build sterile manufacturing skills and a market before taking on the far harder biotechnology of making the active ingredient. It is the same path set out in Pakistan’s vaccine policy.
Where the openings are
- Sterile filling: aseptic lines, isolators, cleanrooms and environmental monitoring.
- Cold chain: insulin must be stored and moved under refrigeration.
- Biotech capability: purification equipment, bioprocess skills and QC laboratories for the second phase.
Why insulin matters in Pakistan
Pakistan has one of the largest populations of people living with diabetes in the world, and many of them depend on insulin every day. Supply relies mainly on imports, which leaves it and prices exposed to exchange rates and to decisions made by a small number of global producers. Local production would not remove that exposure overnight, but it would add a domestic source for a medicine that patients cannot go without.
The products
The three Rosinsulin products cover the common types of human insulin: a short-acting (regular) insulin, an intermediate-acting insulin and a premixed 30/70 combination of the two. These human insulins remain widely used, particularly where cost matters, alongside newer analogue insulins.
How insulin is made
Modern insulin is produced by biotechnology. Microorganisms are engineered to produce a precursor of the insulin protein, which is then extracted, converted and purified through a series of chromatography and processing steps into the active ingredient. That active ingredient is formulated into a sterile solution or suspension and filled into vials or cartridges. Each stage needs specialised equipment and expertise:
| Stage | Key requirements |
|---|---|
| Fermentation | Bioreactors, cell banks, process control |
| Purification | Chromatography, filtration, analytical testing |
| Formulation and filling | Aseptic processing to Annex 1 standards |
| Distribution | Refrigerated storage and transport |
Phase one of the project covers only the last two rows; phase two adds the biotechnology. That is why the second phase is three times as expensive and three years longer.
Skills as well as equipment
Biotech manufacturing depends on people: microbiologists, bioprocess engineers, analytical chemists and quality specialists with experience of biological products. Technology transfer agreements usually include training, and partnerships with universities can help build the next generation of staff. Pakistan’s vaccine ambitions will draw on the same skills, so each project that succeeds strengthens the base for the next.
What patients could gain
For people living with diabetes, the benefits of local production would be practical rather than dramatic: an additional, domestic source of a medicine they cannot go without, less exposure to import delays and currency swings, and, over time, potentially more stable prices. Those benefits depend on the plant meeting international quality standards — which is why DRAP’s stage-wise monitoring and the sterile manufacturing requirements described in our Annex 1 article matter as much as the investment itself.
What to watch
The timelines are long and the details come from unnamed sources; progress against DRAP’s stage-wise monitoring will show whether the project stays on track.
Sterile manufacturing and cleanroom suppliers exhibit at Pharma Asia 2026.
